Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.45 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.45 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.43 |
| ▸ | CCR6 | P51684 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.41 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 2/20 | 0.41 |
| ▸ | RAF1 | P04049 | 1/20 | 0.41 |
| ▸ | LIPE | Q05469 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2520145 | 0.80 | LIPE (0.45) | HDAC3HDAC1HDAC2TRPV1LIPE | |
| SCHEMBL5255954 | 0.75 | GCGR (0.41) | KDM2BEPHX2TRPV1LIPE | |
| SCHEMBL2515824 | 0.75 | GCGR (0.41) | KDM2BEPHX2TRPV1LIPE | |
| SCHEMBL2515957 | 0.73 | EPHX2 (0.47) | HDAC3HDAC1HDAC2EPHX2NR1H4 | |
| SCHEMBL2516384 | 0.72 | USP30 (0.42) | KCNH2SCN5ASCN9AHDAC3HDAC1 | |
| SCHEMBL2515969 | 0.71 | HDAC3 (0.45) | HDAC3HDAC1HDAC2EPHX2NR1H4 | |
| SCHEMBL2229141 | 0.71 | CHRNA7 (0.64) | — | |
| SCHEMBL2229129 | 0.71 | CHRNA7 (0.64) | — | |
| SCHEMBL5252110 | 0.70 | USP30 (0.51) | KCNH2SCN5ASCN9AHDAC3HDAC1 | |
| SCHEMBL2517945 | 0.70 | USP30 (0.51) | KCNH2SCN5ASCN9AHDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8034949-B2 | Pyrrolidine compound and a process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-10-11 | — | — | US | disclosed |
| US-20070167440-A1 | Novel pyrrolidine compound and a process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-07-19 | — | — | US | disclosed |
| EP-1748980-A1 | PYRROLIDINE DERIVATIVES AS CB1-RECEPTOR ANTAGONISTS | TANABE SEIYAKU CO., LTD. (JP) | 2007-02-07 | — | — | EP | disclosed |
| WO-2005115977-A1 | PYRROLIDINE DERIVATIVES AS CB1-RECEPTOR ANTAGONISTS | TANABE SEIYAKU CO., LTD. (JP) | 2005-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167440-A1 | Novel pyrrolidine compound and a process for preparing the same | CNR1, CNR2, OPRD1 | SSTR4 291/4885KCNH2 521/4885SCN5A 1151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.